1 Of
1006 patients who underwent randomization, 1005 were included in t
2 Of the
1050 patients who underwent randomization, 1046 were included in t
3 Of
122 patients who underwent randomization, 116 were included in th
4 Of the
150 patients who underwent randomization, 1 patient died during t
5 Of the
151 patients who underwent randomization, 27 died by 12 weeks and
6 Of the
168 patients who underwent randomization (57 in the brodalumab 14
7 Of the
1931 patients who underwent randomization, in the per-protocol ana
8 Of
216 patients who underwent randomization and received at least on
9 Of
265 patients who underwent randomization, 136 were assigned to th
10 Of the
281 patients who underwent randomization, 280 were included in th
11 Of
318 patients who underwent randomization, 281 (88%) could be eval
12 Of the
326 patients who underwent randomization, the first 218 (109 in e
13 Of the
397 patients who underwent randomization, data from 2 were exclud
14 Of the
40 patients who underwent randomization, all 10 (100%) who recei
15 Of
429 patients who underwent randomization, 415 were eligible.
16 Among the
440 patients who underwent randomization and were treated, 20% ha
17 Of the
4494 patients who underwent randomization, 4482 (99.7%) could be e
18 Of the
500 patients who underwent randomization in the original trial, 2
19 Of the
510 patients who underwent randomization, 509 received tezacaftor
20 Final outcomes were assessed for 496 of
551 patients who underwent randomization.
21 The
6068 patients who underwent randomization were followed for a medi
22 Among the
62 patients who underwent randomization, imatinib treatment redu
23 A total of 65 of the
66 patients who underwent randomization completed the double-bli
24 Of the
804 patients who underwent randomization, 798 were included in th
25 Of the
854 patients who underwent randomization, 33 (3.9%) had a new dia
26 Of the
865 patients who underwent randomization and were treated, 16% ha
27 Of the
90 patients who underwent randomization, 79 completed the trial.
28 Efficacy and safety outcomes for
all patients who underwent randomization and transplantation were
29 rituximab, or severe infection) after transplantation
among patients who underwent randomization.
30 Of
the patients who underwent randomization, 6509 (85.2%) had establ